CiplaCPLFY 94 Net Margin % is 8.58% as of Mar. 2026, which is 29% below its 10-year median of 12.06. GuruFocus rates CPLFY with a GF Score™ of 94/100. The stock has 3 warning signs investors should review. Among 956 Drug Manufacturers companies, Cipla ranks better than 76.26% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cipla's Net Income for the
three
months ended in Mar. 2026 was $59.76 Mil. Cipla's Revenue for the
three
months ended in Mar. 2026 was $696.44 Mil. Therefore, Cipla's net margin for the quarter that ended in Mar. 2026 was 8.58%.
The historical rank and industry rank for Cipla's Net Margin % or its related term are showing as below:
CPLFY'
s Net Margin % Range Over the Past 10 Years
Min: 7.17 Med: 12.06 Max: 19.42
Current: 14
CPLFY's Net Margin % is ranked better than 76.26% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs CPLFY: 14.00
Cipla (OTCPK:CPLFY) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cipla Net Margin % Related Terms
Cipla Net Margin % Historical Data
* Premium members only.
The historical data trend for Cipla's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cipla's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipla (CPLFY) has a Net Margin % of 8.58% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cipla and its competitors. This is 29% below median its historical median of 12.06. Over the past decade, Cipla's Net Margin % has ranged from 7.17 to 19.42. According to the industry distribution chart, Cipla ranks #227 out of 956 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is Cipla's Net Margin % too high?
Cipla's current Net Margin % of 8.58% is 29% below median its 10-year median of 12.06. Over the past 10 years, this metric has ranged from a low of 7.17 to a high of 19.42. The Drug Manufacturers industry median Net Margin % is 5.56. Cipla's value of 8.58% is 54.3% above this industry median. Based on the distribution chart, Cipla ranks #227 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #227 out of 956 companies for Net Margin %. This places Cipla in the top 24% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Cipla's value of 8.58% is 54.3% above this benchmark. Historically, Cipla's own Net Margin % has ranged from 7.17 to 19.42 over the past decade. While the company's 10-year median is 12.06 vs. the industry median of 5.56, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current Net Margin % of 8.58% is 54.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current Net Margin % is 8.58%, which is 29% below median its own 10-year median of 12.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current Net Margin % of 8.58%. The current Net Margin % is 8.58%, which is 29% below median its 10-year median of 12.06 and 54.3% above the Drug Manufacturers industry median of 5.56. Cipla's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cipla (CPLFY), the current Net Margin % is 8.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPLFY has been successfully added to your 